ESMO Expert Commentary | Roxadustat Non-inferior to Standard Treatment, Poised to Transform Clinical Practice in Chemotherapy-Induced Anemia

ESMO Expert Commentary | Roxadustat Non-inferior to Standard Treatment, Poised to Transform Clinical Practice in Chemotherapy-Induced Anemia

Platinum-based, taxane, anthracycline, and other chemotherapy drugs are commonly used in the treatment of various cancers such as breast and lung cancer. However, these chemotherapy agents, known marrow suppressors, can lead to chemotherapy-induced anemia (CIA), resulting in a decline in functional capacity and diminished quality of life for patients. This year's ESMO conference revealed the results of a Phase III clinical study on roxadustat in treating CIA in patients with non-myeloid malignancies, offering a more convenient treatment option for CIA patients. "Oncology Frontier" is honored to invite Professor Yongmei Yin from Jiangsu Provincial People's Hospital and Professor Jian Zhang from Fudan University Cancer Hospital to share insights into the current challenges in CIA treatment and the significance of this study for CIA patients.
ESMO Big Shot Interview | Professor Feng Wang: Significant Efficacy of Sintilimab Combined with Apatinib and Bevacizumab in the Treatment of MSS/pMMR Metastatic Colorectal Cancer, Promising Future

ESMO Big Shot Interview | Professor Feng Wang: Significant Efficacy of Sintilimab Combined with Apatinib and Bevacizumab in the Treatment of MSS/pMMR Metastatic Colorectal Cancer, Promising Future

The 2023 European Society for Medical Oncology (ESMO) Annual Meeting was held in Madrid, Spain from October 20 to 24. The Oncology Frontier Reporting Team delved into the frontiers of international advancements, witnessing the progress of China's anti-cancer efforts on the global stage. Professor Feng Wang from Sun Yat-sen University Cancer Center presented an important oral report at this conference. In an interview with "Oncology Frontier," Professor Feng Wang shared insights into two studies and highlights in the field of gastric cancer at the ESMO conference. This issue compiles relevant content for readers.
WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), was held in Singapore from September 9th to 12th. " Oncology Frontier" invited Zhu Zhengfei from Fudan University-affiliated Cancer Hospital to comment on the findings of the COSINR study.
The Value of Lepidic and Invasion Patterns New Diagnostic Criteria for the Differential Diagnosis of AIS, MIA from Invasive Adenocarcinoma

The Value of Lepidic and Invasion Patterns New Diagnostic Criteria for the Differential Diagnosis of AIS, MIA from Invasive Adenocarcinoma

At the 2023 World Conference on Lung Cancer (WCLC), Dr. Xie Huikang from Shanghai Pulmonary Hospital presented a study titled " The Value of Lepidic and Invasion Pattern NEW Diagnostic Criteria for the Differential Diagnosis of AIS, MIA from Invasive Adenocarcinoma ." The study aimed to explore whether the new IASLC definitions and standards had an impact on the diagnosis of AIS, MIA, and IAC compared to previous criteria.
WCLC Voice of China | Dr. Liang Application of Video-Based Artificial Intelligence in Thoracoscopic Lobectomy for Lung Cancer

WCLC Voice of China | Dr. Liang Application of Video-Based Artificial Intelligence in Thoracoscopic Lobectomy for Lung Cancer

From September 9th to 12th, 2023, the World Conference on Lung Cancer (WCLC) was held in Singapore. Oncology Frontier deeply engaged in the conference, capturing the latest advancements and witnessing the progress and strides made by China in the international oncology arena. Dr. Liang Hengrui of the First Affiliated Hospital of Guangzhou Medical University presented the results from Chinese researchers in the field of "Artificial Intelligence Application in Thoracoscopic Lobectomy for Lung Cancer" in a brief oral report at the 2023 WCLC.